Aequim Alternative Investments LP - THERAVANCE BIOPHARMA INC ownership

THERAVANCE BIOPHARMA INC's ticker is and the CUSIP is 88339KAA0. A total of 23 filers reported holding THERAVANCE BIOPHARMA INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.3%.

Quarter-by-quarter ownership
Aequim Alternative Investments LP ownership history of THERAVANCE BIOPHARMA INC
ValueSharesWeighting
Q2 2022$13,814,000
+4.9%
15,000,000
+7.8%
0.42%
+21.9%
Q1 2022$13,173,000
-2.5%
13,920,0000.0%0.35%
-17.8%
Q4 2021$13,509,000
+4.6%
13,920,0000.0%0.42%
-15.3%
Q3 2021$12,909,000
+18.7%
13,920,000
+21.9%
0.50%
+6.9%
Q2 2021$10,878,000
+256.3%
11,420,000
+280.7%
0.47%
+136.5%
Q1 2021$3,053,000
+7.5%
3,000,0000.0%0.20%
-5.7%
Q4 2020$2,840,0003,000,0000.21%
Other shareholders
THERAVANCE BIOPHARMA INC shareholders Q3 2021
NameSharesValueWeighting ↓
Context Capital Management, LLC 6,000,000$5,827,0003.55%
DeepCurrents Investment Group LLC 21,223,000$20,803,0001.80%
ZAZOVE ASSOCIATES LLC 19,230,000$18,725,0001.77%
Mohican Financial Management, LLC 500,000$494,0001.61%
Castle Creek Arbitrage, LLC 5,149,000$5,015,0001.47%
LINDEN ADVISORS LP 62,688,000$61,071,0001.40%
Verition Fund Management LLC 10,817,000$10,504,0000.41%
WOLVERINE ASSET MANAGEMENT LLC 24,100,000$23,451,0000.32%
Baupost Group 30,000,000$29,213,0000.24%
SSI INVESTMENT MANAGEMENT LLC 2,763,000$2,676,0000.22%
View complete list of THERAVANCE BIOPHARMA INC shareholders